AEGiS-14IAC: Retrospective analysis of nelfinavir containing antiretroviral combinations in treatment experienced patients.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Retrospective analysis of nelfinavir containing antiretroviral combinations in treatment experienced patients.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10192)

Weiss SE, Cervia JS, Dali P, Freeman K
Long Island Jewish Medical Center, New Hyde Park, United States

BACKGROUND: Prior studies have reported the impact of Nelfinavir containing antiretroviral combinations in profoundly suppressing HIV replication. There is little data however, involving treatment experienced individuals with advanced disease.

METHODS: We retrospectively analyzed the records of 24 HIV infected, antiretroviral experienced patients who were followed at our center. Viral load, CD4 count and CD4 percentage were assessed at 3 timepoints; prior to initiation of a Nelfinavir containing regimen, 8 weeks after starting treatment and either at discontinuation of Nelfinavir or last results available. Genotypic data was available for 8 patients, 2 prior to Nelfinavir initiation and the remainder while on therapy.

RESULTS: Median follow-up in this cohort was 12 months ( range 2-30 months). Statistically significant differences were observed in both viral load reduction and CD4 count increases. Median viral load at time of Nelfinavir initiation and post treatment were 4.31 log and 3.21 log respectively (P< 0.05). Median CD4 count increase was 161 cells/mm3 (range -238 to +537; P< 0.05). Genotypic data was notable for the absence of the D30N mutation, most often associated with Nelfinavir resistance. Only 1 patient had discontinued Nelfinavir due to an adverse event (diarrhea).

CONCLUSION: Antiretroviral regimens containing Nelfinavir were both safe and effective. Our analysis showed statistically significant viral load reductions and CD4 count increases in a cohort of antiretroviral experienced patients with advanced HIV disease.

Keywords: AEGIS, Nelfinavir, CD4 Lymphocyte Count, Viral Load, Anti-HIV Agents, HIV Protease Inhibitors, HIV Infections, Retrospective Studies, Antiretroviral Therapy, Highly Active, HIV, Drug Therapy, Combination, HIV Protease, Human, therapy, drug therapyKWDaegis,nelfinavir,cd4lymphocytecount,viralload,anti-hivagents,hivproteaseinhibitors,hivinfections,retrospectivestudies,antiretroviraltherapy,highlyactive,hiv,drugtherapy,combination,hivprotease,human,therapy,drugtherapy

020707
B10192

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.